CSL (ASX:CSL) shares rose nearly 1% in morning trade Monday after the biotechnology company secured marketing authorization from Health Canada for Andembry as a once-monthly treatment for hereditary angioedema attacks in adult and pediatric patients aged 12 years and older.
Andembry is designed to target activated FXII, a plasma protein that plays a key role in the attacks, according to the company's Friday, Aug. 8 release.
Hereditary angioedema is a rare and potentially life-threatening genetic disorder characterized by recurrent and unpredictable attacks of swelling in various parts of the body.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。